MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Dai Horiuchi(Northwestern University), Andrei Goga(Howard Hughes Medical Institute)
Cited by 395
Related Papers
S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models
|Communications Medicine|2024|7
S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1
Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0